ICU Medical, Inc.

Healthcare · Medical - Instruments & Supplies

Overall research band Weak

Quality Very weak

Valuation Very weak

Balance sheet Very weak

Market confirmation Above average

One-minute company read

What this report can tell you now

What the company does

ICU Medical, Inc. is a global medical technology company headquartered in San Clemente, California, specializing in the development, manufacture, and sale of devices for infusion therapy and critical care. Its product portfolio includes needlefree connectors (MicroClave, MicroClave Clear, NanoClave), catheter maintenance and disinfection devices (Neutron, SwabCap, SwabTip), hemodialysis solutions (Tego, ClearGuard HD), hazardous drug handling systems (ChemoClave, ChemoLock, Diana), intravenous solutions and irrigation fluids in various packaging, and advanced infusion pumps (Plum 360, LifeCare PCA) integrated with MedNet software for medication safety. The company also offers hemodynamic monitoring systems (Cogent 2-in-1, CardioFlo), cardiac output and oximetry catheters (TDQ, OptiQ, TriOx), blood pressure transducers (Transpac), and closed blood sampling systems (SafeSet).

The current research profile is Turnaround Candidate, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC2.6%Model input; read with the evidence status and period context.

Operating margin4.8%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years14.1%Model input; read with the evidence status and period context.

FCF margin4.1%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.